{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T13:19:02Z","timestamp":1785417542443,"version":"3.56.0"},"reference-count":17,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2022-I2M-1-022"],"award-info":[{"award-number":["2022-I2M-1-022"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2022-I2M-JB-015"],"award-info":[{"award-number":["2022-I2M-JB-015"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007737","name":"St Jude Children's Research Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007737","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012524","name":"American Lebanese Syrian Associated Charities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012524","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2019YFA0110803"],"award-info":[{"award-number":["2019YFA0110803"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870131"],"award-info":[{"award-number":["81870131"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.clml.2023.04.012","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T22:13:33Z","timestamp":1683756813000},"page":"660-666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia"],"prefix":"10.1016","volume":"23","author":[{"given":"Xiaolan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingliao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongjun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0303-5658","authenticated-orcid":false,"given":"Ching-Hon","family":"Pui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.04.012_bib0001","doi-asserted-by":"crossref","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","article-title":"Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005","volume":"28","author":"Arico","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.04.012_bib0002","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","article-title":"Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study","volume":"27","author":"Schultz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.04.012_bib0003","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2023.04.012_bib0004","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","article-title":"Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study","volume":"13","author":"Biondi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.04.012_bib0005","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","article-title":"Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial","volume":"5","author":"Biondi","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.04.012_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1002\/cam4.383","article-title":"Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from Japanese Pediatric Leukemia\/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04","volume":"4","author":"Manabe","year":"2015","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2023.04.012_bib0007","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","article-title":"Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: results of Children's Oncology Group Trial AALL0622","volume":"36","author":"Slayton","year":"2018","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2023.04.012_bib0008","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/blood.V130.Suppl_1.98.98","article-title":"An international collaborative phase 2 trial of dasatinib and chemotherapy in pediatric patients with newly diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)","volume":"130","author":"Hunger","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0009","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1001\/jamaoncol.2019.5868","article-title":"Effect of dasatinib vs imatinib in the treatment of pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: a randomized clinical trial","volume":"6","author":"Shen","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clml.2023.04.012_bib0010","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood-2019-124295","article-title":"An updated safety and efficacy results of phase I study of HQP1351, a novel 3rd generation of BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI resistant chronic myeloid leukemia","volume":"134","author":"Jiang","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0011","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1182\/blood-2020-142142","article-title":"Novel BCR-ABL1 tyrosine kinase inhibitor (TKI) HQP1351 (olverembatinib) is efficacious and well tolerated in patients with T315I-mutated chronic myeloid leukemia (CML): results of pivotal (phase II) trials","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0012","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1182\/blood-2022-170698","article-title":"Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation","volume":"140","author":"Jiang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0013","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/blood-2022-162387","article-title":"Olverembatinib (HQP1351) overcomes ponatinib resistance in patients with heavily pretreated\/refractory chronic myeloid leukemia (CML) and Phiadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL)","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0014","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood-2022-170868","article-title":"A five-year follow-up on safety and efficacy of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) in China","volume":"140","author":"Jiang","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0015","doi-asserted-by":"crossref","first-page":"11683","DOI":"10.1182\/blood-2022-165879","article-title":"Olverembatinib plus low-intensive regimen in frontline therapy for newly diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: a case series from a single center","volume":"140","author":"Lou","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0016","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/blood-2022-166482","article-title":"The first report of third-generation TKI olverembatinib in adult Ph\/BCR-ABL1-positive acute lymphoblastic leukemia with T315I mutation and relapsed disease","volume":"140","author":"Liu","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.04.012_bib0017","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/CAD.0000000000001455","article-title":"Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study","volume":"34","author":"Tan","year":"2023","journal-title":"Anticancer Drugs"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:51Z","timestamp":1761871371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":17,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S2152265023001404"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}